Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program

▤ Summary

Pentixapharm secured FDA clearance for its IND and can now start its U.S.-focused Phase 3 PANDA study. The program tests a first-in-class CXCR4-targeted imaging approach for patient stratification in treatment-resistant hypertension and primary aldosteronism. The company says the study supports a registrational strategy and could improve how clinicians identify and treat this underdiagnosed condition. Pentixapharm also signals active partner discussions and financing efforts to support Phase 3 work and U.S. expansion.

▦ Linked Companies